These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers]. Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308 [TBL] [Abstract][Full Text] [Related]
3. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis. Kobayashi H; Obata K Cancer Chemother Pharmacol; 1994; 35 Suppl():S14-7. PubMed ID: 7994781 [TBL] [Abstract][Full Text] [Related]
4. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity]. Igawa M; Kadena H; Ohkuchi T; Ueda M; Usui T Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1627-36. PubMed ID: 1770701 [TBL] [Abstract][Full Text] [Related]
5. Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin chemotherapy for advanced urothelial cancers. Ogawa T; Gotoh A; Takenaka A; Hara I; Gohji K; Arakawa S; Matsumoto O; Kamidono S Cancer Chemother Pharmacol; 1992; 30 Suppl():S66-71. PubMed ID: 1394822 [TBL] [Abstract][Full Text] [Related]
6. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer]. Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405 [TBL] [Abstract][Full Text] [Related]
7. [M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced renal pelvic and ureteral carcinoma]. Igawa M; Ueki T; Ueda M; Okada K; Usui T; Ohnishi Y; Kume T; Masu C; Ishino T; Nakatsu H Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2577-82. PubMed ID: 2673046 [TBL] [Abstract][Full Text] [Related]
9. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma]. Narita S; Nakano M; Matsuzaki M; Watanabe J; Morikawa H; Murata H; Oda H; Komatsu H Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667 [TBL] [Abstract][Full Text] [Related]
10. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer. Miyanaga N; Akaza H; Shimazui T; Ohtani M; Koiso K Cancer Chemother Pharmacol; 1994; 35 Suppl():S5-8. PubMed ID: 7527735 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of urothelial tract tumors. Yagoda A Cancer; 1987 Aug; 60(3 Suppl):574-85. PubMed ID: 3297286 [TBL] [Abstract][Full Text] [Related]
12. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161 [TBL] [Abstract][Full Text] [Related]
13. Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study. Pizzocaro G; Milani A; Piva L; Faustini M; Spino E Eur Urol; 1991; 20(2):89-92. PubMed ID: 1752280 [TBL] [Abstract][Full Text] [Related]
14. [Clinical efficacy of modified M-VAC chemotherapy for advanced urothelial carcinoma and influence of squamous cell carcinoma-associated antigen on efficacy of the chemotherapy]. Otani N; Kumamoto Y; Tsukamoto T; Miyao N; Iwabe H; Yanase M; Takahashi A; Masumori N Nihon Hinyokika Gakkai Zasshi; 1991 May; 82(5):786-91. PubMed ID: 1875572 [TBL] [Abstract][Full Text] [Related]
15. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer]. Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216 [TBL] [Abstract][Full Text] [Related]
16. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. Sternberg CN; Yagoda A; Scher HI; Watson RC; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N; Weiselberg LR J Urol; 1988 Mar; 139(3):461-9. PubMed ID: 3343727 [TBL] [Abstract][Full Text] [Related]
17. Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) for advanced TCC of urothelium. Huang CH; Hsieh HH; Wang JM; Hsu K; Yang WC; Yu TJ J Formos Med Assoc; 1992 Jul; 91(7):699-703. PubMed ID: 1360298 [TBL] [Abstract][Full Text] [Related]
18. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Sternberg CN; Yagoda A; Scher HI; Watson RC; Geller N; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N Cancer; 1989 Dec; 64(12):2448-58. PubMed ID: 2819654 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Dodd PM; McCaffrey JA; Mazumdar M; Scher H; Vlamis V; Higgins G; Herr H; Bajorin DF Cancer; 1999 Mar; 85(5):1145-50. PubMed ID: 10091800 [TBL] [Abstract][Full Text] [Related]
20. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management]. Noguchi S; Kubota Y; Shuin T; Masuda M; Misaki H; Yao M; Kondoh K; Sakuramoto T; Hosaka M Hinyokika Kiyo; 1994 Aug; 40(8):677-82. PubMed ID: 7942364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]